In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until today.Angiotensin-converting enzyme 2(ACE2),a ...In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until today.Angiotensin-converting enzyme 2(ACE2),a receptor of SARS-CoV-2,mediates the virus infection by binding to spike protein.Although ACE2 is expressed in the lung,kidney,and intestine,its expressing levels are rather low,especially in the lung.Considering the great infectivity of COVID-19,we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection.Here,we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein.The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody,Meplazumab,inhibits SARSCoV-2 amplification.Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells,which can be neutralized by CD147 extracellular fragment.Viral loads are detectable in the lungs of human CD147(hCD147)mice infected with SARS-CoV-2,but not in those of virus-infected wild type mice.Interestingly,virions are observed in lymphocytes of lung tissue from a COVID-19 patient.Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dosedependent manner,which is specifically inhibited by Meplazumab.Furthermore,CD147 mediates virus entering host cells by endocytosis.Together,our study reveals a novel virus entry route,CD147-spike protein,which provides an important target for developing specific and effective drug against COVID-19.展开更多
AIM:To elucidate the clinicopathological characteristics and prognostic factors of gastric stump cancer(GSC).METHODS:The clinical data for 92 patients with GSC were collected at Fudan University Shanghai Cancer Center...AIM:To elucidate the clinicopathological characteristics and prognostic factors of gastric stump cancer(GSC).METHODS:The clinical data for 92 patients with GSC were collected at Fudan University Shanghai Cancer Center.The prognostic factors were analyzed with Cox proportional hazard models.RESULTS:GSC tended to occur within 25 years following the primary surgery,when the initial disease is benign,whereas it primarily occurred within the first15 years post-operation for gastric cancer.Patients with regular follow-up after primary surgery had a better survival rate.The multivariate Cox regression analysis revealed that Borrmann type?Ⅰ/Ⅱ(HR=3.165,95%CI:1.055-9.500,P=0.040)and radical resection(HR=1.780,95%CI:1.061-2.987,P=0.029)were independent prognostic factors for GSC.The overall 1-,3-,and 5-year survival rates of the 92 patients were78.3%,45.6%and 27.6%,respectively.The 1-,3-,and 5-year survival rates of those undergoing radical resection were 79.3%,52.2%,and 37.8%,respectively.The 5-year survival rates for stages?Ⅰ,Ⅱ,Ⅲ,andⅣwere 85.7%,47.4%,16.0%,and 13.3%,respectively(P=0.005).CONCLUSION:The appearance of GSC occurs sooner in patients with primary malignant cancer than in patients with a primary benign disease.Therefore,close follow-up is necessary.The overall survival of patients with GSC is poor,and curative resection can improve their prognosis.展开更多
Meplazumab,a humanized CD147 antibody,has shown favourable safety and efficacy in our previous clinical studies.In DEFLECT(NCT04586153),167 patients with severe COVID-19 were enroled and randomized to receive three do...Meplazumab,a humanized CD147 antibody,has shown favourable safety and efficacy in our previous clinical studies.In DEFLECT(NCT04586153),167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo.Meplazumab at 0.12 mg/kg,compared to the placebo group,showed clinical benefits in significantly reducing mortality by 83.6%(2.4%vs.14.6%,p=0.0150),increasing the proportion of patients alive and discharged without supplemental oxygen(82.9%vs.70.7%,p=0.0337)and increasing the proportion of patients who achieved sustained clinical improvement(41.5%vs.31.7%).The response rate in the 0.2 mg/kg group was relatively increased by 16.0%compared with the placebo group(53.7%vs.46.3%).Meplazumab also reduced the viral loads and multiple cytokine levels.Compare with the placebo group,the 0.3 mg/kg significantly increased the virus negative rate by 40.6%(p=0.0363)and reduced IL-8 level(p=0.0460);the 0.2 mg/kg increased the negative conversion rate by 36.9%,and reduced IL-4(p=0.0365)and IL-8 levels(p=0.0484).In this study,the adverse events occurred at a comparable rate across the four groups,with no unexpected safety findings observed.In conclusion,meplazumab promoted COVID-19 convalescence and reduced mortality,viral load,and cytokine levels in severe COVID-19 population with good safety profile.展开更多
In this work, a three-layer TiO2 composite film consisting of flower-like TiO2 （Flo-TiO2） as overlayer, TiOa nanotube arrays as interlayer and TiO2 nanoparticle （P25） as underlayer was fabricated as the photoelect...In this work, a three-layer TiO2 composite film consisting of flower-like TiO2 （Flo-TiO2） as overlayer, TiOa nanotube arrays as interlayer and TiO2 nanoparticle （P25） as underlayer was fabricated as the photoelectrode of dyesensitized solar cells （DSSCs）. Due to the introduction of Flo-TiO2, the three-layer composite film has strong lightscattering ability. Then, we have investigated and compared the photoelectric conversion properties of DSSCs based on three-layer structure （P25/TNT arrays/Flo-TiO2） photoelectrode and double-layer film （P25/TNT arrays） photoelectrode. It is found that DSSCs based on three-layer structure exhibit a high power conversion efficiency of 6.48% compared with the DSSCs composed of double-layer film （5.11%）.展开更多
In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until today.Angiotensin-converting enzyme 2(ACE2),a ...In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until today.Angiotensin-converting enzyme 2(ACE2),a receptor of SARS-CoV-2,mediates the virus infection by binding to spike protein.Although ACE2 is expressed in the lung,kidney,and intestine,its expressing levels are rather low,especially in the lung.Considering the great infectivity of COVID-19,we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection.Here,we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein.The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody,Meplazumab,inhibits SARSCoV-2 amplification.Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells,which can be neutralized by CD147 extracellular fragment.Viral loads are detectable in the lungs of human CD147(hCD147)mice infected with SARS-CoV-2,but not in those of virus-infected wild type mice.Interestingly,virions are observed in lymphocytes of lung tissue from a COVID-19 patient.Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dosedependent manner,which is specifically inhibited by Meplazumab.Furthermore,CD147 mediates virus entering host cells by endocytosis.Together,our study reveals a novel virus entry route,CD147-spike protein,which provides an important target for developing specific and effective drug against COVID-19.展开更多
Background Cardiovascular disease(CVD)is a common cause of death in China.There have been many evidences that inflammatory factors and acute phase reactants play an important role in the pathogenesis of coronary heart...Background Cardiovascular disease(CVD)is a common cause of death in China.There have been many evidences that inflammatory factors and acute phase reactants play an important role in the pathogenesis of coronary heart disease and acute coronary syndromes,and their related factors may become indicators for predicting and diagnosing early cardiovascular disease.Recent evidence has shown that human cartilage glycoprotein 39(YKL-40)is related to metabolic disorders caused by inflammatory diseases and heart diseases.YKL-40 is a new type of inflammation marker.Studies have shown that YKL-40 can further aggravate vascular damage and can be used as a biomarker for assessing the severity of cardiovascular disease and judging the prognosis.This article reviewed the biological characteristics of YKL-40 and its relationship with cardiovascular diseases.[S Chin J Cardiol 2021;22(1):57-64]展开更多
In recent years,the incidence of myocarditis has been increasing year by year. The clinical manifestations of patients vary greatly with common symptoms in infants and young children and atypical clinical manifestatio...In recent years,the incidence of myocarditis has been increasing year by year. The clinical manifestations of patients vary greatly with common symptoms in infants and young children and atypical clinical manifestations in most adults. Patients with severe myocarditis may have serious concurrent symptoms,such as arrhythmia,cardiac insufficiency or even sudden death. Because of its lack of specificity in clinical manifestations and auxiliary examination results,and its insufficient understanding of pathogenesis,the diagnosis is difficult. Therefore,early diagnosis and treatment of patients with myocarditis is particularly important. This article reports on patients with myocarditis misdiagnosed as myocardial infarction,hoping to provide ideas for clinical diagnosis of myocarditis.[S Chin J Cardiol 2019;20(2):125-130]展开更多
Background Myocardial hypertrophy is an adaptive and compensatory response to pathological changes caused by circulatory overload and various factors.Myocardial hypertrophy have been a hot research topic in the field ...Background Myocardial hypertrophy is an adaptive and compensatory response to pathological changes caused by circulatory overload and various factors.Myocardial hypertrophy have been a hot research topic in the field of cardiovascular medicine.The research mainly involves the mechanism of myocardial hypertrophy and the development of effective drugs to prevent or slow down myocardial hypertrophy and myocardial remodeling.A large number of studies have shown that many Chinese medicine monomers may play a role in preventing the occurrence of myocardial hypertrophy.In order to understand the perspectives and development of traditional Chinese medicine monomers in the treatment of myocardial hypertrophy,this article reviewed the mechanism of various traditional Chinese medicine monomers in the treatment of myocardial hypertrophy.[S Chin J Cardiol 2021;22(1):65-68]展开更多
基金supported by the National Science and Technology Major Project of China(2019ZX09732-001)the Key R&D Plan Projects in Shaanxi Province(2020ZDXM2-SF-01)Young Talent fund of the University Association for Science and Technology in Shaanxi,China(20200304).
文摘In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until today.Angiotensin-converting enzyme 2(ACE2),a receptor of SARS-CoV-2,mediates the virus infection by binding to spike protein.Although ACE2 is expressed in the lung,kidney,and intestine,its expressing levels are rather low,especially in the lung.Considering the great infectivity of COVID-19,we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection.Here,we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein.The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody,Meplazumab,inhibits SARSCoV-2 amplification.Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells,which can be neutralized by CD147 extracellular fragment.Viral loads are detectable in the lungs of human CD147(hCD147)mice infected with SARS-CoV-2,but not in those of virus-infected wild type mice.Interestingly,virions are observed in lymphocytes of lung tissue from a COVID-19 patient.Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dosedependent manner,which is specifically inhibited by Meplazumab.Furthermore,CD147 mediates virus entering host cells by endocytosis.Together,our study reveals a novel virus entry route,CD147-spike protein,which provides an important target for developing specific and effective drug against COVID-19.
基金Supported by National Natural Science Foundation of China,No.81272726Specialized Research Fund for the Doctoral Program of Higher Education,China,No.20110071120097Shanghai Municipal Health Bureau Research Project,No.20114174
文摘AIM:To elucidate the clinicopathological characteristics and prognostic factors of gastric stump cancer(GSC).METHODS:The clinical data for 92 patients with GSC were collected at Fudan University Shanghai Cancer Center.The prognostic factors were analyzed with Cox proportional hazard models.RESULTS:GSC tended to occur within 25 years following the primary surgery,when the initial disease is benign,whereas it primarily occurred within the first15 years post-operation for gastric cancer.Patients with regular follow-up after primary surgery had a better survival rate.The multivariate Cox regression analysis revealed that Borrmann type?Ⅰ/Ⅱ(HR=3.165,95%CI:1.055-9.500,P=0.040)and radical resection(HR=1.780,95%CI:1.061-2.987,P=0.029)were independent prognostic factors for GSC.The overall 1-,3-,and 5-year survival rates of the 92 patients were78.3%,45.6%and 27.6%,respectively.The 1-,3-,and 5-year survival rates of those undergoing radical resection were 79.3%,52.2%,and 37.8%,respectively.The 5-year survival rates for stages?Ⅰ,Ⅱ,Ⅲ,andⅣwere 85.7%,47.4%,16.0%,and 13.3%,respectively(P=0.005).CONCLUSION:The appearance of GSC occurs sooner in patients with primary malignant cancer than in patients with a primary benign disease.Therefore,close follow-up is necessary.The overall survival of patients with GSC is poor,and curative resection can improve their prognosis.
基金The DEFLECT is supported by grants from National Natural Science Foundation of China(No.92169211).Jiangsu Pacific Meinuoke Biopharmaceuticals provided meplazumab.The views expressed in this article is the authors’opinion,not the opinion or policy of funder.
文摘Meplazumab,a humanized CD147 antibody,has shown favourable safety and efficacy in our previous clinical studies.In DEFLECT(NCT04586153),167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo.Meplazumab at 0.12 mg/kg,compared to the placebo group,showed clinical benefits in significantly reducing mortality by 83.6%(2.4%vs.14.6%,p=0.0150),increasing the proportion of patients alive and discharged without supplemental oxygen(82.9%vs.70.7%,p=0.0337)and increasing the proportion of patients who achieved sustained clinical improvement(41.5%vs.31.7%).The response rate in the 0.2 mg/kg group was relatively increased by 16.0%compared with the placebo group(53.7%vs.46.3%).Meplazumab also reduced the viral loads and multiple cytokine levels.Compare with the placebo group,the 0.3 mg/kg significantly increased the virus negative rate by 40.6%(p=0.0363)and reduced IL-8 level(p=0.0460);the 0.2 mg/kg increased the negative conversion rate by 36.9%,and reduced IL-4(p=0.0365)and IL-8 levels(p=0.0484).In this study,the adverse events occurred at a comparable rate across the four groups,with no unexpected safety findings observed.In conclusion,meplazumab promoted COVID-19 convalescence and reduced mortality,viral load,and cytokine levels in severe COVID-19 population with good safety profile.
基金supported by the National Natural Science Foundation of China (Nos. 51572072 and 11204070)the Fundamental Research Funds for the Central Universities (No. 2014-Ia-028)financially supported by State Key Laboratory of Advanced Technology for Materials Synthesis and Processing (No. 2016-KF-13)
文摘In this work, a three-layer TiO2 composite film consisting of flower-like TiO2 （Flo-TiO2） as overlayer, TiOa nanotube arrays as interlayer and TiO2 nanoparticle （P25） as underlayer was fabricated as the photoelectrode of dyesensitized solar cells （DSSCs）. Due to the introduction of Flo-TiO2, the three-layer composite film has strong lightscattering ability. Then, we have investigated and compared the photoelectric conversion properties of DSSCs based on three-layer structure （P25/TNT arrays/Flo-TiO2） photoelectrode and double-layer film （P25/TNT arrays） photoelectrode. It is found that DSSCs based on three-layer structure exhibit a high power conversion efficiency of 6.48% compared with the DSSCs composed of double-layer film （5.11%）.
基金This work was supported by the National Science and Technology Major Project of China(2019ZX09732-001)the Key R&D Plan Projects in Shaanxi Province(2020ZDXM2-SF-01)Young Talent fund of the University Association for Science and Technology in Shaanxi,China(20200304).
文摘In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until today.Angiotensin-converting enzyme 2(ACE2),a receptor of SARS-CoV-2,mediates the virus infection by binding to spike protein.Although ACE2 is expressed in the lung,kidney,and intestine,its expressing levels are rather low,especially in the lung.Considering the great infectivity of COVID-19,we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection.Here,we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein.The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody,Meplazumab,inhibits SARSCoV-2 amplification.Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells,which can be neutralized by CD147 extracellular fragment.Viral loads are detectable in the lungs of human CD147(hCD147)mice infected with SARS-CoV-2,but not in those of virus-infected wild type mice.Interestingly,virions are observed in lymphocytes of lung tissue from a COVID-19 patient.Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dosedependent manner,which is specifically inhibited by Meplazumab.Furthermore,CD147 mediates virus entering host cells by endocytosis.Together,our study reveals a novel virus entry route,CD147-spike protein,which provides an important target for developing specific and effective drug against COVID-19.
基金supported by Science and Technology Key Research Project in Jining(No.2018SMNS006)Teaching Case Library Project of 2018 Professional Degree Graduate Student in Shandong Province(No.SDYAL18100)
文摘Background Cardiovascular disease(CVD)is a common cause of death in China.There have been many evidences that inflammatory factors and acute phase reactants play an important role in the pathogenesis of coronary heart disease and acute coronary syndromes,and their related factors may become indicators for predicting and diagnosing early cardiovascular disease.Recent evidence has shown that human cartilage glycoprotein 39(YKL-40)is related to metabolic disorders caused by inflammatory diseases and heart diseases.YKL-40 is a new type of inflammation marker.Studies have shown that YKL-40 can further aggravate vascular damage and can be used as a biomarker for assessing the severity of cardiovascular disease and judging the prognosis.This article reviewed the biological characteristics of YKL-40 and its relationship with cardiovascular diseases.[S Chin J Cardiol 2021;22(1):57-64]
文摘In recent years,the incidence of myocarditis has been increasing year by year. The clinical manifestations of patients vary greatly with common symptoms in infants and young children and atypical clinical manifestations in most adults. Patients with severe myocarditis may have serious concurrent symptoms,such as arrhythmia,cardiac insufficiency or even sudden death. Because of its lack of specificity in clinical manifestations and auxiliary examination results,and its insufficient understanding of pathogenesis,the diagnosis is difficult. Therefore,early diagnosis and treatment of patients with myocarditis is particularly important. This article reports on patients with myocarditis misdiagnosed as myocardial infarction,hoping to provide ideas for clinical diagnosis of myocarditis.[S Chin J Cardiol 2019;20(2):125-130]
基金supported Science and Technology Key Research Project in Jining(No.2018SMNS006)Teaching Case Library Project of 2018 Professional Degree Graduate Student in Shandong Province(No.SDYAL18100)
文摘Background Myocardial hypertrophy is an adaptive and compensatory response to pathological changes caused by circulatory overload and various factors.Myocardial hypertrophy have been a hot research topic in the field of cardiovascular medicine.The research mainly involves the mechanism of myocardial hypertrophy and the development of effective drugs to prevent or slow down myocardial hypertrophy and myocardial remodeling.A large number of studies have shown that many Chinese medicine monomers may play a role in preventing the occurrence of myocardial hypertrophy.In order to understand the perspectives and development of traditional Chinese medicine monomers in the treatment of myocardial hypertrophy,this article reviewed the mechanism of various traditional Chinese medicine monomers in the treatment of myocardial hypertrophy.[S Chin J Cardiol 2021;22(1):65-68]
